Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal

Overview

Journal Microorganisms

Specialty Microbiology

Date 2020 Jan 26

PMID 31979032

Citations 68

Authors

Sofia Costa-de-Oliveira

Acacio G Rodrigues

Affiliations

Soon will be listed here.

Abstract

represents the most frequent isolated yeast from bloodstream infections. Despite the remarkable progress in diagnostic and therapeutic approaches, these infections continue to be a critical challenge in intensive care units worldwide. The economic cost of bloodstream fungal infections and its associated mortality, especially in debilitated patients, remains unacceptably high. is a highly adaptable microorganism, being able to develop resistance following prolonged exposure to antifungals. Formation of biofilms, which diminish the accessibility of the antifungal, selection of spontaneous mutations that increase expression or decreased susceptibility of the target, altered chromosome abnormalities, overexpression of multidrug efflux pumps and the ability to escape host immune defenses are some of the factors that can contribute to antifungal tolerance and resistance. The knowledge of the antifungal resistance mechanisms can allow the design of alternative therapeutically options in order to modulate or revert the resistance. We have focused this review on the main factors that are involved in antifungal resistance and tolerance in patients with C. albicans bloodstream infections.

Citing Articles

Pyridoxal and Salicylaldehyde Derivatives: Synthesis, Characterization, and Antifungal Potential Against Opportunistic Yeast Pathogens.

Camacho J, Bejarano C, Diaz J, Vargas-Casanova Y, Carvajal S, Diaz Santoyo V Molecules. 2025; 30(5).

PMID: 40076387 PMC: 11901757. DOI: 10.3390/molecules30051165.

Molecular and biological characteristics of two rare bloodstream Candida isolates: Candida nonsorbophila and Candida sonorensis.

Li R, Chen J, Wu Y, Lu M, Cheng G, Jia P BMC Infect Dis. 2025; 25(1):348.

PMID: 40075268 PMC: 11905472. DOI: 10.1186/s12879-025-10696-x.

Development of Miniprotein-Type Inhibitors of Biofilm Formation in and .

Kim D, Kim J, Bai X, Zhang J, Park M, Lee U J Microbiol Biotechnol. 2025; 35:e2411076.

PMID: 40016146 PMC: 11896806. DOI: 10.4014/jmb.2411.11076.

A Comparative Review of Eugenol and Citral Anticandidal Mechanisms: Partners in Crimes Against Fungi.

Shahina Z, Dahms T Molecules. 2024; 29(23).

PMID: 39683696 PMC: 11643759. DOI: 10.3390/molecules29235536.

Characterization of a New Hsp110 Inhibitor as a Potential Antifungal.

Sun C, Li Y, Kidd J, Han J, Ding L, May A J Fungi (Basel). 2024; 10(11).

PMID: 39590652 PMC: 11595998. DOI: 10.3390/jof10110732.

References

Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y . Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis. 2007; 67(3):380-8. DOI: 10.1136/ard.2007.070821. View

Sanglard D, Ischer F, Marchetti O, Entenza J, Bille J . Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol Microbiol. 2003; 48(4):959-76. DOI: 10.1046/j.1365-2958.2003.03495.x. View

Tanabe K, Bonus M, Tomiyama S, Miyoshi K, Nagi M, Niimi K . FK506 Resistance of Pdr5 and Cdr1 Involves Mutations in the Transmembrane Domains and Extracellular Loops. Antimicrob Agents Chemother. 2018; 63(1). PMC: 6325234. DOI: 10.1128/AAC.01146-18. View

Stergiopoulou T, Meletiadis J, Sein T, Papaioannidou P, Tsiouris I, Roilides E . Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. J Antimicrob Chemother. 2008; 63(2):343-8. PMC: 2734084. DOI: 10.1093/jac/dkn473. View

Yan L, Li M, Cao Y, Gao P, Cao Y, Wang Y . The alternative oxidase of Candida albicans causes reduced fluconazole susceptibility. J Antimicrob Chemother. 2009; 64(4):764-73. DOI: 10.1093/jac/dkp273. View

Montagna M, Lovero G, Borghi E, Amato G, Andreoni S, Campion L . Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci. 2014; 18(5):661-74. View

Sanglard D, Ischer F, Calabrese D, Majcherczyk P, Bille J . The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother. 1999; 43(11):2753-65. PMC: 89555. DOI: 10.1128/AAC.43.11.2753. View

Perlin D . Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007; 10(3):121-30. PMC: 2696280. DOI: 10.1016/j.drup.2007.04.002. View

Katragkou A, Roilides E, Walsh T . Role of Echinocandins in Fungal Biofilm-Related Disease: Vascular Catheter-Related Infections, Immunomodulation, and Mucosal Surfaces. Clin Infect Dis. 2015; 61 Suppl 6:S622-9. DOI: 10.1093/cid/civ746. View

10.

Quindos G . Epidemiology of candidaemia and invasive candidiasis. A changing face. Rev Iberoam Micol. 2013; 31(1):42-8. DOI: 10.1016/j.riam.2013.10.001. View

11.

Larkin E, Dharmaiah S, Ghannoum M . Biofilms and beyond: expanding echinocandin utility. J Antimicrob Chemother. 2018; 73(suppl_1):i73-i81. DOI: 10.1093/jac/dkx451. View

12.

Nolla-Salas J, Sitges-Serra A, Leon-Gil C, Martinez-Gonzalez J, Leon-Regidor M, Ibanez-Lucia P . Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU. Intensive Care Med. 1997; 23(1):23-30. DOI: 10.1007/s001340050286. View

13.

Pedrosa A, Rodrigues A . Candidemia in burn patients: figures and facts. J Trauma. 2011; 70(2):498-506. DOI: 10.1097/TA.0b013e3181f2d4fb. View

14.

Kawamura A, Su M . Interaction of FKBP12-FK506 with calcineurin A at the B subunit-binding domain. J Biol Chem. 1995; 270(26):15463-6. DOI: 10.1074/jbc.270.26.15463. View

15.

Morschhauser J, Barker K, Liu T, BlaB-Warmuth J, Homayouni R, Rogers P . The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog. 2007; 3(11):e164. PMC: 2048531. DOI: 10.1371/journal.ppat.0030164. View

16.

Pfaller M, Messer S, Rhomberg P, Jones R, Castanheira M . In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol. 2013; 51(8):2608-16. PMC: 3719620. DOI: 10.1128/JCM.00863-13. View

17.

Verwer P, van Duijn M, Tavakol M, Bakker-Woudenberg I, van de Sande W . Reshuffling of Aspergillus fumigatus cell wall components chitin and β-glucan under the influence of caspofungin or nikkomycin Z alone or in combination. Antimicrob Agents Chemother. 2011; 56(3):1595-8. PMC: 3294952. DOI: 10.1128/AAC.05323-11. View

18.

Pfaller M, Diekema D, Turnidge J, Castanheira M, Jones R . Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Species From 1997-2016. Open Forum Infect Dis. 2019; 6(Suppl 1):S79-S94. PMC: 6419901. DOI: 10.1093/ofid/ofy358. View

19.

Pappas P, Kauffman C, Andes D, Benjamin Jr D, Calandra T, Edwards Jr J . Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009; 48(5):503-35. PMC: 7294538. DOI: 10.1086/596757. View

20.

dEnfert C . Hidden killers: persistence of opportunistic fungal pathogens in the human host. Curr Opin Microbiol. 2009; 12(4):358-64. DOI: 10.1016/j.mib.2009.05.008. View